



Transformational Research Awards (2026-2027)

Expression Of Interest (EOI) - Guidance for Applicants

Introduction

Blood Cancer UK's [five-year strategy](#) is focused on bringing forward the day when no one dies of blood cancer or its treatments. To help us reach this aim, we are committed to increasing the funding we have available for world quality research and maximising the support we provide for the vibrant community of exceptional blood cancer researchers working across the UK.

Blood Cancer UK's current [research strategy](#) outlines how we will invest in research over the period 2025-2030. We will continue to fund research across all blood cancer types and our three key priority research themes will be prevention, early detection and outcome prediction, and treatment. A key element of the strategy is also ensuring we fund across the pipeline from discovery to clinical research.

Through the charity's Transformational Research Awards scheme, Blood Cancer UK intends to support ambitious, high-quality research that aims to make substantial progress towards a [transformational change](#) for people with blood cancer or a precursor condition.

The charity acknowledges that what can be considered a 'transformational' change will vary by the blood cancer/precursor type/s the research is focused on. Blood Cancer UK also understands that this ultimate transformational impact for patients can either be as a direct result of the proposed research or following further research/downstream investment.

2026-2027 awards

This year, Blood Cancer UK is inviting applications for research that aligns with one of the priority areas outlined below from our current research strategy and that aims to make substantial progress towards a transformational change for people with any type of blood cancer or a precursor condition, from any age group (including children and young people).



With that in mind, in the relevant sections of their EOI, applicants should clearly outline:

- how their research is meeting at **least one** of the following priority areas:
 - **Prevention** - identifying people at risk of developing blood cancer, and/or targeting pre-malignant disease to prevent blood cancers.
 - **Early detection and prognosis** - ensuring early and timely diagnosis and/or predicting outcome/disease progression.
 - **Treatment** – developing more effective treatments, decreasing the toxicity and side effects of treatments, finding effective combinations of targeted treatments for each patient, preventing relapse and/or preventing transformation to more aggressive forms of blood cancer.
- the specific transformational change they are aiming to make progress towards through their proposed research and how this change could be transformational for the blood cancer/precursor population/s of interest.
- how the proposed research will accelerate progress towards the desired change for people with or at risk of developing blood cancer.

We encourage applications across all forms of blood cancer and have a core funding pot of up to £3 million to fund the scheme this year.

In addition we strongly encourage applications in the field of myeloma for which further ring-fenced funding is available from the Matthew Wilson Multiple Myeloma Fund for the highest quality fundable application.

Remit

This scheme is designed to support:

Research type	Notes
Advanced/late-stage translational and pre-clinical research	This includes the late-stage translational development, pre-clinical refinement and testing of one or more specific interventions designed to improve the prevention, diagnosis, prognosis, or treatment of blood cancer with the aim of moving the intervention along the developmental pathway to early phase clinical studies or trials after this award.
Clinical and experimental medicine (including clinical studies or trials)	This includes clinical studies or trials of any phase or design, and the addition of new cohorts to an existing trial or study. However, Blood Cancer UK appreciates that the budget and duration of the grants available through the Transformational Research Awards scheme naturally limits what sort of



	study/trial can be proposed (i.e., more likely to be an earlier-phase trial of a 'simpler' and/or traditional/classical/fixed design).
Research to accelerate the uptake of new treatments and other interventions into the NHS	This includes primary research to assess the clinical and cost-effectiveness of a promising intervention in comparison to the standard of care/the current best alternative.

- Grants will typically be awarded for **up to five years** and for a **maximum of £1,500,000**. However, the charity can consider applications that are over a slightly longer timeframe where there is strong justification for doing so. Any such requests must be discussed with the Blood Cancer UK Research team before submitting an EOI.
- This scheme is designed to support ambitious, high-quality projects that drive research forward towards patient benefit so Blood Cancer UK would expect applicants to typically request a grant of at least £500,000, with most non-clinical applications requesting £750,000-£1,000,000 and most clinical applications requesting from £1.0-1.5 million.

Applications for smaller-scale projects should be submitted to the charity's annual Project Grants scheme that is next opening in October 2026.

- All applicants, including those applying for funding for advanced/late-stage pre-clinical research, must clearly define the immediate next steps for their research (e.g., a phase I clinical trial) and the overall pathway to clinical uptake into the NHS or wider UK health system, and to real-world impact for patients.
- For applicants applying for funding to support a clinical study or trial, Blood Cancer UK encourages the integration of sample collection and translational research within the proposal (such as hypothesis-testing mechanistic studies), where this adds value and where the budget allows their inclusion and delivery to a sufficient standard.

The charity would expect the funding relating to these activities to be no more than 20% of the overall budget requested, but Blood Cancer UK can consider larger requests if sufficiently justified and discussed with the Research team before submission of your EOI.

Otherwise, applicants that are successful in securing a Transformational Research Award are welcome to [apply to Blood Cancer UK](#) for separate funding for any research that is associated with their study or trial,



through the charity's Innovative Pilot Grant, Project Grant, or Early Career Fellowship schemes.

Please note that the securing of any other grant is subject to the charity's standard, rigorous application and review procedures and without preference over any other application received into the same round of each scheme.

- The proposed research should be inclusive by design and have an inclusive recruitment strategy in place to ensure people are recruited who are representative of the disease group/subgroups under investigation.
- Please note that applications for, or focusing primarily on, biobanks and/or infrastructure are **not** in remit for this scheme.

Get in touch

If you wish to discuss if your proposed research is within remit for this year's scheme, please do get in touch with the Blood Cancer UK Research Office at research@bloodcancer.org.uk and the team would be happy to advise.

Eligibility

- Individuals based at UK universities, hospitals or other recognised research institutions who are able to sign up to [Blood Cancer UK's Terms and Conditions](#) are eligible to apply.
- Applicants should have at a minimum some postdoctoral research experience, or equivalent, and be scientists, clinicians or healthcare professionals.
- The lead applicant should usually have a permanent or long-term rolling contract, with their salary paid by the Host Institution for the duration of the award.
- Researchers who do not meet the criteria above can apply as the main applicant and include a request for their own salary support if required. However, applicants in this category must include a co-applicant with tenure based at their Host Institution.
- This scheme is not open to applicants employed by a commercial organisation.



Timelines

Call for Expressions of Interest (EOI) opens: **Thursday 23rd April 2026**

Deadline for EOI submissions: **3pm on Thursday 4th June 2026**

Applicants notified of EOI outcomes: **July 2026**

Deadline for submission of invited full applications: **November 2026**

Applicants notified of outcomes: **March 2027**

Application process

All applications must be submitted via the **new Blood Cancer UK Grants Portal**. The portal is used for submission, peer review, award, and monitoring of all grant applications. Instructions on how to use the portal will be provided on our website. Please follow these to complete and submit an application. The application can be stored and edited at any time prior to submission.

The application deadline is **3:00pm on the date advertised (see above)**. No applications will be accepted after the deadline. Applicants should allow enough time for submission of their applications before the deadline to ensure all the required approvals are obtained.

For any enquiries about completing the application form or submitting your application, please contact research@bloodcancer.org.uk.

Assessment of applications

EOIs for this scheme will be reviewed and shortlisted by Blood Cancer UK's Clinical Trials Review Committee and a subset of the charity's Research Funding Committee to ensure the assembled committee covers the breadth of applications it may receive into this scheme. The committee will also include people affected by blood cancer who are experts by experience.



Assessment criteria used for the shortlisting of EOIs will include:

- **Relevance:** How relevant is this research for people affected by blood cancer?
- **Originality/novelty:** Is the proposed research duplicative of previous or current research? Does the proposed research address a gap in current knowledge?
- **Unmet need & transformational change:** Have the researchers identified an unmet need? How likely is it that the change they are proposing to work towards will be transformational for their target blood cancer/precursor condition population?
- **Priority alignment:** Does the proposed research meet at least one of the priority areas from the current Blood Cancer UK research strategy?
- **Impact potential:** How likely is it that this research will accelerate progress towards the desired transformational change? Is there a clear line of sight from the proposed research to clinical uptake in the NHS or real-world impact for people affected by blood cancer?
- **Proposed approach:** Is the research proposal clear and feasible and how likely is it that the aims and objectives of the research can be reached? Are the estimated costs reasonable at this stage?
- **Expertise:** Does the research team have the track record and expertise required to successfully achieve the aims of the proposed research?
- **Patient and Public Involvement:** To what extent have the researchers involved people affected by blood cancer in the development of their research proposal? Have they either developed, or shown sufficient evidence that they will develop, sufficient plans for ongoing involvement throughout the planned research?

Shortlisted applicants will be invited to submit a full application. At that stage, such applicants will receive both the shortlisting committee's feedback and some additional guidance relating to the submission of a full application.



Completing the Expression of Interest form

Please complete the form as fully and accurately as you can at this stage. Blood Cancer UK does understand that some details or plans are only preliminary at the EOI stage and may be subject to change in a full application.

Please read the following guidance notes carefully as you complete the EOI form:

EOI form section	Guidance notes
Proposal Summary	
Title of Proposal	Please give the full title of your proposed research.
Duration (months)	Please note that the maximum grant duration for this scheme is 60 months unless otherwise agreed with Blood Cancer UK in advance of submitting an EOI.
Total Amount Requested (£)	This box auto populates from the costs provided in the 'Estimated Finances and Costs' section of this form.
Synopsis	<p>The synopsis should be a scientific abstract of the proposed research. This should include the background, the key research question/s, aims and objectives, and brief details of the proposed methodology. Applicants should also briefly outline the transformational change that could result from this research and how this research will accelerate progress towards the desired change.</p> <p>Please note there is a word limit of 200 words for this section.</p>
Host Institution	<p>The name of the Host Institution where this award will be based.</p> <p>Please note - if you are invited to submit a full application and are then successful in securing funding, the Host Institution where the award will be held must be able to sign up to Blood Cancer UK's Terms and Conditions of award.</p>
Proposed Start Date	Please note - awarded grants are expected to be activated by the grant holder within three months from the start date indicated on the Grant Award Letter. Applicants should allow enough time to recruit staff members and to gain any required approvals.
Previously Submitted to Blood Cancer UK?	Indicate whether the application is a new submission, continuation of a current or recently closed award, or a resubmission.

B

	<p>If it is a continuation, please provide the start date of your previous grant, its title, and the grant number.</p> <p>If it is a resubmission, please provide the date of your original submission, its title and the submission reference number.</p>
Is your proposal associated with a clinical study or trial?	<p>Please indicate whether the application is associated with a clinical study or trial, if known at this stage.</p> <p>If so, please state the names of the study/s and/or trial/s and, if applicable, a recognised trial registry number such as ISRCTN or ClinicalTrials.gov.</p> <p>If the study/s and/or trial/s are supported by Blood Cancer UK, please also add the grant reference numbers.</p>
Scientific Proposal Details	
Research proposal (1,500 words max)	<p>Please provide an overview of your proposed research.</p> <p>For all research types, please include:</p> <ul style="list-style-type: none">– A clear description of the target population this research will focus on, the current standard of care for this population, the specific unmet need you are aiming to address, and the transformational change you are aiming to make progress towards through your proposed research and how this change could be transformational for the blood cancer/precursor population/s of interest.– The background and rationale behind your proposal including an overview of how it builds on existing knowledge, from your work and others, and why now is the right time to undertake this research.– The specific research question/s, aims and objectives of this research.– A summary of your plan of investigation and proposed methods.– An overview of how this research will help meet the unmet need you have identified. <p>If your proposed research involves the <u>use of animals</u>, please also include:</p> <ul style="list-style-type: none">– A brief overview of the planned experiments.– The specific species and model/s you plan to use.– Whether these animals are genetically modified.– The rationale behind your choice of model/s. <p>If your proposal <u>includes a clinical study or trial</u>, please also include:</p>

B

	<ul style="list-style-type: none">- The proposed sponsor and CTU. Where the application involves a clinical trial, <u>full</u> submissions are expected to be developed with the participation of the relevant Clinical Trials Unit (CTU).- An overview of your choice of design and justification of this choice, including and where applicable:<ul style="list-style-type: none">▪ Why this design was chosen over other possible designs.▪ Planned intervention/s.▪ Duration of treatment.▪ Target population.▪ Inclusion and exclusion criteria and how these will be assessed.▪ Outcome measures and endpoints.▪ Recruitment strategy and targets.- An overview of your statistical analysis and/or bioinformatics plan, including justification power calculations and sample sizes.- An overview of any planned associated sample collections and/or any translational research such as hypothesis-testing mechanistic studies. <p>Supporting data including figures, tables, and illustrations cannot be included in the text and should be submitted as supporting documents below or later in the application and referenced in the application text boxes. You are permitted to submit up to 4 A4 pages of supporting data alongside this application.</p>
<p>Downstream plan and potential impact of the proposal (1,000 words max)</p>	<p>The primary aim of this funding scheme is to accelerate progress towards a transformational change that will improve the lives of people with or at risk of developing blood cancer.</p> <p>To be successful, applicants should use this section to clearly describe how the proposed work will achieve that aim.</p> <p>The ultimate transformational impact for patients can either be as a direct result of the proposed research, or following further research and/or downstream investment, but applicants are asked to clearly define:</p> <ul style="list-style-type: none">- the progress towards the identified transformational change for people with or at risk of blood cancer that will be made during the research itself.- the immediate next steps including any follow-on research investment that would be required and whether that would be sought from Blood

B

	<p>Cancer UK, other charities, UKRI, NIHR, industry or other sources.</p> <ul style="list-style-type: none">– the overall pathway to clinical uptake into the NHS or wider UK health system and to real-world impact for patients, including an indication of the key regulatory requirements that will need to be met. <p>If applicable, please also describe how this research could impact people with blood cancer or precursor conditions, other cancer types, or other conditions, beyond the target population of the research.</p>
<p>Related applications and current funding (500 words max)</p>	<p>Please use this section to provide the following information, where applicable:</p> <ul style="list-style-type: none">– If this application has been <u>submitted elsewhere in the past year</u>, detail the organisation and outcome of the submission.– If this application is <u>currently being submitted elsewhere</u>, please add the organisation and the expected decision date.– If your related research is <u>currently being supported by another funding organisation</u>, please provide the following details for <u>each</u> grant:<ul style="list-style-type: none">▪ Funder name.▪ Grant holder name(s).▪ Grant title.▪ Total grant awarded (and how much you received).▪ Your role in the research.▪ Grant start and end dates.– If there is active research in your research group/laboratory related to the topic of this application, please explain how this application fits within this broader research activity, confirm that this application is for a distinct area of research and that there is no overlap in the funding being requested.– If you receive additional core funding or support from the proposed Host Institution for the award, and/or the main applicant's employing institution if different to the Host Institution, briefly describe the resources provided.



Support from other sources & IP and commercialisation management (500 words max)

Will funding and/or support from other organisations, core infrastructure and/or third-party contracting be required to deliver the proposed research? This includes any aspects of the work to be delivered in partnership or contracted out to third party organisations.

Please provide details of any organisations involved in the delivery of the proposed research and description of their involvement. Please also confirm if funding, support and/or formal agreements are already in place or being applied for/negotiated.

Blood Cancer UK welcomes the involvement of commercial partners in the proposed research, where this is sufficiently detailed and justified. If your application involves commercial partners, please provide strong justification why this project requires charitable funding and cannot not be undertaken as part of commercial R&D.

If your proposed research is likely to lead to patentable or otherwise commercially exploitable results, please confirm if you have spoken to your Technology Transfer Office (TTO).

Blood Cancer UK has a partnership with Cancer Research Horizons who manage IP and commercialisation on the charity's behalf. If you have any questions or concerns in relation to IP and/or commercialisation, Blood Cancer UK is happy to arrange a meeting between you and Cancer Research Horizons to discuss these in more detail, ahead of either an EO1 or full submission.

IP is defined as patents, copyright, trademarks, trade names, service marks, domain names copyrights, moral rights, rights in and to databases (including rights to prevent the extraction or re-utilisation of information from a database), design rights, topography rights and all rights or forms of protection of a similar nature or having equivalent or the similar effect to any of them which may subsist anywhere in the world, whether or not any of them are registered and including applications for registration of any of them.

At the full application stage, Blood Cancer UK strongly encourages the inclusion of letters of support from partner/third party organisations involved in the delivery of significant elements of the proposed research where applicable.

If your application includes any collaboration with a commercial partner (for example the provision of free drug, equipment, or of an educational grant, or of partial funding for elements of the project), at the full application stage, you will be asked to provide a letter of support from the partner demonstrating their support for the proposed research, outlining any contribution(s) to be made, and that they would



be willing in principle to fulfil these contributions subject to funding being secured.

Plain English Proposal Details

This is the main section of the application that people affected by blood cancer from Blood Cancer UK's Research Involvement Network are asked to review, although Blood Cancer UK will make the rest of the application available to them too.

This entire section should be completed using plain English, non-technical language and avoiding unexplained acronyms and/or abbreviations. This section is intended for a lay audience, and it is important that the description of the proposed research is accessible.

They will provide feedback on:

- The relevance of the research to them as someone affected by blood cancer.
- The clarity of the plain English section of the application (and whether they can understand what the proposed research aims to achieve).
- Whether patient and public involvement has been considered and if they have any feedback or additional considerations to share about involving people affected by blood cancer.

Please note that the accessibility of this section will directly impact the likelihood of your EOI being shortlisted as it is part of the scoring criteria used by the Research Involvement Network representatives during the funding committee meeting for the EOI stage of this round.

For detailed guidance on writing for people affected by blood cancer, please see [this page](#) on the charity's website.

Please note that the word limit for your response to each question is 200 words.

Plain English Title	Provide a full research title in non-technical language.
Plain English Summary	Please provide a summary of the proposed research for a non-specialist audience. This should be a lay abstract of the proposed research.
Background	Outline what the background is to this application. Is it a continuation of your existing or current research, or is it a new area?
Research need	Why is this research needed? How many people in the UK are affected by the condition(s) and what treatment options are currently available? Please clearly outline the specific transformational change in prevention, diagnosis, prognosis, or treatment that you are working towards.
Research Questions and Aims/Objectives	What is/are the research question(s) being addressed and why? What are the aims and objectives? If your proposal includes a clinical study or trial, please also include:

B

	<ul style="list-style-type: none">- Who can take part in the research and how they will be recruited?- What will taking part in the research involve?- What are the benefits of taking part in this research?- What are the potential risks and side effects for people taking part?
Impact and Benefits	<p>What is the potential impact of this research for people affected by blood cancer? What will the next steps be after this research and how will this work lead to the transformational change that you are aiming towards? If successful, when could the benefits of your research reach patients?</p> <p>Does your research have the potential to have a broader impact and relevance to all or other blood cancers or precursor conditions, in addition to the specific disease/s being studied?</p>
Patient and Public Involvement (PPI)	<p>Blood Cancer UK expects meaningful Patient and Public Involvement (PPI) to be embedded in <u>all</u> research funded through this scheme.</p> <p>Specifically, the charity strongly encourages the involvement of people affected by blood cancer in the development of your EOI. The charity expects the involvement of people affected by blood cancer in the development of your full application, if you are invited to submit one, and throughout the research itself.</p> <p>Have you already involved people affected by blood cancer in shaping your EOI? What are your plans to involve people affected by blood cancer, members of the public or non-academic communities in the development of your full application and throughout the research itself?</p> <p>How will you keep people (including PPI contributors, study/trial participants and the wider public) informed about research progress and the final results?</p> <p>Please note that PPI is separate to the recruitment of patients or members of the public as participants in a trial or study.</p> <p>For further guidance, please visit this page on the charity's website.</p>



	<p>Blood Cancer UK is happy to support you with your PPI. Please contact research@bloodcancer.org.uk if you would like further support as soon as possible and <u>no later than 2 weeks before</u> the EOI submission deadline. For example, the charity provides a matchmaking service with PPI representatives from its involvement network.</p>
References	
References	<p>Include references for the research outlined in this application.</p> <p>You are permitted a maximum of 3 pages and 10 Mb attachment size. You can upload .doc, docx, pdf, jpg, jpeg, png, tiff, attachments.</p>
Estimated Finance and Costs	
<p>Please note that the maximum budget available for this grant type will typically be £1,500,000. Any requests for larger amounts must be discussed with Blood Cancer UK <u>before</u> submitting an application.</p>	
<p>For this first EOI stage of the application process, please provide an approximate figure for the total amount you are likely to request for the duration of the grant for each budget line listed below.</p>	
<p>The following information on eligible and ineligible costs is given for guidance of what will be accepted in a full stage proposal to help you prepare your estimated budget. Please see the specific guidance for each budget line in the boxes below.</p>	
<u>Eligible costs</u>	
<p>As a member of the Association of Medical Research Charities, Blood Cancer UK will only fund directly incurred costs and not the full economic costs of the research. The charity will <u>not</u> fund directly allocated costs or indirect costs.</p>	
<p>Directly-incurred costs (direct costs of the research) are costs that are explicitly identifiable as arising from the conduct of the research, are charged in the cash value actually spent, and are supported by an audit record. These include:</p>	
<ul style="list-style-type: none">- Salaries- Equipment- Animals- Recurrent Costs	
<p><u>For applications involving clinical studies or trials</u></p>	
<p>At the full application stage, applicants are expected to outline the NHS cost implications for their proposed study or trial and provide a summary of the estimated costs and your plans for seeking support for any Excess Treatment Costs.</p>	
<p>You must complete a Schedule of Events Costs Attribution Template (SoECAT) if you are applying for research funding, and will do your research in the UK, and need Health Research</p>	



Authority approval for your study. If you meet these criteria, you must complete a SoECAT even if you do not think your research will involve excess treatment costs (ETCs).

The SoECAT ensures that costs are attributed in line with the AcoRD principles consistently across the UK. It helps to produce a full picture of the site-level study activities to understand the resource implications involved for different parties:

- activities that are research costs will be supported by the grant funder
- activities that are service support costs will be supported by the NIHR RDN (if the study is eligible for the NIHR RDN Portfolio) in England
- any excess treatment costs (ETCs) will be supported by the Department of Health and Social Care based on the SoECAT-derived ETC per participant value in England, with payments administered by the NIHR RDN via the National Payment System.

At the full application stage, your SoECAT must be signed off by an AcoRD specialist ahead of the full application deadline, and you are asked to submit the completed Funder Export file from the validated SoECAT as part of the TRA application form.

As Blood Cancer UK is a member of the Association of Medical Research Charities (AMRC), Blood Cancer UK will only fund the costs for activities attributed to the **Research Part A Costs** category, in line with the [Department of Health \(DoH\) AcoRD guidelines](#).

The following costs should NOT be included in the budget requested from Blood Cancer UK in your application:

- Research Part B Costs (the NHS pays these costs where the funder is an AMRC member);
- NHS Treatment or Service Support Costs;
- Excess Treatment Costs (ETCs).

At the full stage, any Research Part A costs that are not salaries or equipment should be included within recurrent costs. For your EOI, please simply add an estimate of the Research Part A costs to the Recurrent Costs amount and justify this in the relevant section, if possible at this stage.

We strongly recommended that you engage with your Lead NIHR Regional Research Delivery Network and their AcoRD Specialists as soon as possible during the TRA funding process. Please see the [NIHR SoECAT Guidance](#) for more information.

Generally, you must ensure the study or trial is suitably resourced to enable timely and efficient set up. For example, NHS research costs must be attributed correctly and there should be sufficient resource in place during set up to facilitate efficient regulatory and contract approvals to take place.

Ineligible costs

- **Directly-allocated costs** – shared costs, based on estimates that do not represent actual costs on a project-by-project basis, such as:
 - Investigators - the estimated time spent by the lead applicant, joint lead applicants, co-applicants and co-investigators cannot be included unless otherwise specified in the salary guidance given.
 - Estates.
 - Shared resources, such as administrative and clerical staff and equipment.
- **Indirect costs** – necessary for underpinning research but that cannot be allocated to individual projects, such as:
 - Computing and information support.



- Central services.
- General maintenance and other infrastructure costs.
- Costs relating to staff recruitment and relocation costs.
- Funding to provide maintenance and/or insurance of equipment.
- Office stationery costs unless required for the project and justified accordingly.
- Indemnity insurance.
- Publication costs - award holders can [apply for publication costs](#) separately during the award.
- Ineligible clinical study or trial costs as detailed above.

Please now enter the details of the estimated finances required for this grant. The estimated total will be calculated automatically.

Salaries	<p>Please enter the approximate amount you will request as support for salaries if invited to submit a full application to this round.</p> <p>The following information is given for guidance of what will be accepted in a full stage proposal to help you prepare your estimated budget for this line:</p> <ul style="list-style-type: none">– Transformational Research Awards can support full-time or part-time staff members’ salaries where those salaries are directly incurred costs of the project.– Eligible staff include postdoctoral research assistants, research assistants, technicians and clinical staff, including research nurses.– Researchers acting as a lead applicant, joint lead applicant, co-applicant or co-investigator can only include requests for their own salary support at the %FTE they will dedicate to this project where their salary is not already paid by their employer, a tenureship, a personal fellowship or other grant funding, or where funding is required to buy out clinical time.– Full-time PhD students are not normally permitted to be members of staff on Transformational Research Awards.– Salaries are expected to be costed by the host institution’s research office according to an applicable pay model.– Eligible CTU costs can include funding for posts required for delivery of the study/trial.
Equipment	<p>Please enter the approximate amount you will request as support for equipment if invited to submit a full application to this round.</p> <p>The following information is given for guidance of what will be accepted in a full stage proposal to help you prepare your estimated budget for this line:</p>

B

	<ul style="list-style-type: none">– Blood Cancer UK assumes that there is a basic level of equipment provision by the Host Institution. Applicants can request essential equipment items (including computing and software) that is specific to the needs of the research. At the full application stage, items of equipment greater than £10,000 must include a written quote.
Animals	<p>Please enter the approximate amount you will request as support for animal-related costs if invited to submit a full application to this round.</p> <p>The following information is given for guidance of what will be accepted in a full stage proposal to help you prepare your estimated budget for this line:</p> <ul style="list-style-type: none">– Please include all costs related to the use of animals including costs for purchase, maintenance and experimental procedures.
Recurrent Costs	<p>Please enter the approximate amount you will request as support for recurrent costs if invited to submit a full application to this round.</p> <p>The following information is given for guidance of what will be accepted in a full stage proposal to help you prepare your estimated budget for this line.</p> <p>In this section, please include all other directly incurred costs for this research including research costs and clinical study/trial costs.</p> <p>The following items are examples of common items included under recurrent costs:</p> <ul style="list-style-type: none">– Research Part A costs (non-salary or non-equipment) – for clinical studies or trials (see guidance notes earlier in the document).– Consumables – please specify major items of consumables with accompanying details. For example, if ‘Microarrays’ is an item, please enter the number and type of array in the ‘Justification’ box.– Access charges - for use of specialist equipment. A breakdown must be provided.– Patient and Public Involvement (PPI) costs - costs should be included within recurrent costs. Please provide details of any reimbursement of expenses and/or involvement payments you have, or will, offer to people involved in your research. For further guidance, refer to the UK Standards for Public Involvement.– EDI-related costs – costs required for specific activities or initiatives needed to help ensure the research adheres to the principles of Equality, Diversity

B

	<p>and Inclusion. For example, you may request costs to facilitate recruitment of a representative and diverse group of patients to your proposed study or trial.</p> <ul style="list-style-type: none">– Partner/sub-contracted costs –these must be fully-justified and a detailed breakdown provided for how the total cost associated with any of these was calculated. If necessary to provide sufficient detail, you should include this breakdown in the ‘Justification for support requested section’ or as an application attachment. <p>Travel - travel for conferences to present research outputs directly from the award is an allowable cost for the staff member(s) employed on the grant. Costs include standard travel, accommodation, and conference fees. Blood Cancer UK grant holders are expected to acknowledge Blood Cancer UK in all presentations and/or posters. The maximum allowance for travel to conferences is up to £3,750 per eligible post over five years. Travel costs for conferences must be a separate budget line in the recurrent costs section.</p>
Estimated Total Costs	The system automatically provides a total for the costs requested from the approximate amounts entered above.
Justification for support requested (500 words max)	<p>Please also provide a short justification for the estimated support requested and to cover each of the budget lines, in the text box given.</p> <p>For staff costs requested, a brief outline of responsibilities should be provided, including how each role relates to the objectives and timelines of the study.</p> <p>Please note there is a word limit of 500 words for this section.</p>
Lead Applicant	
Lead Applicant Details	<p>Please provide details for the proposed lead applicant or Principal Investigator (PI) of the research award.</p> <p>The main applicant has overall responsibility for the delivery and reporting of the grant and ensuring that the terms and conditions of the award are met. They should typically be based at the Host Institution for the award unless otherwise agreed with Blood Cancer UK in advance of submitting an EOI.</p> <p>The details provided in this section are those you provide in your new Blood Cancer UK Grants Portal account – please update these in your account by clicking the profile picture in the top right corner of the screen when logged in.</p>
Main Applicant’s CV	



Main applicant's CV	<p>These pre-populated details are those Blood Cancer UK have stored for you. Please ensure that they are accurate. To amend them, save and close the application and visit the profile section.</p> <p>For the EOI stage your ten latest research grants and publications will be pre-populated from your profile.</p>
Additional Applicants	
Additional applicant details	<p>Please use the table provided to list the names of any joint lead applicants, co-applicants, co-investigators, or collaborators, and the organisation/s they work for as a minimum.</p> <ul style="list-style-type: none">• A joint lead applicant is an investigator who will contribute equal time and intellectual input to the research as the lead applicant, with equal overall responsibility for the delivery and reporting of the grant.• A co-applicant is an investigator who will contribute equal time and intellectual input to the research as the lead applicant, but who does not have overall responsibility for delivery and reporting.• A co-investigator is an investigator who will provide significant intellectual input, as well as overseeing some aspects of the experimental work.• A collaborator is an investigator who may provide reagents, advice, or access to research materials, but who will not be directly involved in the day-to-day work. <p>If known at this stage, please also briefly describe what their specific role within the research would be if it was funded.</p> <p>Where possible at this stage, your proposed team should involve, or you should plan to involve, at least one individual that has experience of driving translational and clinical research through to NHS uptake and/or real-world patient benefit (at minimum, as a co-investigator (not collaborator)).</p> <p>If your proposed research includes a clinical trial, you should also include, or plan to include, a statistician in your proposed team (at minimum, as a co-investigator (not collaborator)).</p> <p>Please note that named individuals for both of these roles will be required as part of a full submission where applicable.</p> <p>For research including a clinical trial, Blood Cancer UK also encourages the inclusion of CTU staff at minimum as co-investigators (not collaborators), to provide expertise in trial coordination and management.</p>



	<p>Blood Cancer UK welcomes the inclusion of a PPI contributor as an additional applicant for this scheme, but this is not mandatory. The charity appreciates it is not always as straightforward to provide a named organisation for a PPI contributor, so we are happy to accept 'Blood Cancer UK', the host institution for the award, or the relevant PPI group they're affiliated with as proxies for this (whichever is the most appropriate for the individual in question). If you're still not sure what to put for this, please do get in touch at research@bloodcancer.org.uk.</p> <p>The charity also encourages the involvement of early-career researchers (ECRs) in the development and delivery of the research to facilitate their training.</p> <p>Please indicate these individuals within your answer to this question whether or not any of these roles is fulfilled by the Lead Applicant.</p>
Signatories	
Please add the details of the signatories required to sign off the EOI. Automated emails are sent to both signatories to confirm their participation which is required before you can submit your EOI. Once the EOI has been validated and submitted by the main applicant, the signatories will also be asked to formally approve the application before it is finally submitted to Blood Cancer UK.	
Head of Research Office	Please complete.
Department Head	Please complete.
Classifications	
Target Blood Cancers	Please select each classification relevant to your application from the available list.
Target Population Age	Please select each classification relevant to your application from the available list.
Research Focus Areas	<p>Please select up to four classifications relevant to your application from the Common Scientific Outline (CSO) classification system which groups cancer research grants into six broad areas of scientific focus</p> <p>For further information on CSO classification system please refer to the International Cancer Research Partnership (ICRP) website</p>
Strategic Priority Alignment	Please indicate which of the charities' current research priorities are the main focus of your proposed research. You must tick at least one.
Attachment Summary	
Attachments	<p>Please note that only text can be added to the Proposal Summary and plain English sections of the application form.</p> <p>However, files can be attached to the application. Some file types you attach will be embedded at the end of the</p>



	<p>application file itself. Some file types will be saved in a separate zipped file and referenced in the application form on the 'Attachments' page.</p> <p>In all cases, the embedded or attached files will be visible to the committee assessing the EOI form.</p>
--	--

Submitting your application

To complete your application submission:

1. Once you are sure all questions have been completed correctly you can submit the application by navigating to the attachment summary page of the application and clicking the 'submit' button at the bottom of the page.
2. Automated emails then sent to both your signatories.
3. Both signatories must log on to individually approve submission of the application.
4. The application is then submitted to Blood Cancer UK and email confirmation is sent to the lead applicant.

It is only upon your institutional signatories' approval that the application is finally submitted to Blood Cancer UK so please ensure there is time to complete this step before the 3pm deadline.

By submitting the application, the Host Institution confirms that they can accept the [terms and conditions](#) of any Blood Cancer UK grant, and that space and facilities will be provided for the duration of an award.

Get in touch

If you need assistance at any point during the application process, please do get in touch with the Blood Cancer UK Research Office at research@bloodcancer.org.uk and one of the team will be more than happy to assist you.